66 research outputs found
Recommended from our members
Modern Imaging Technology: Recent Advances
This 2-day conference is designed to bring scientist working in nuclear medicine, as well as nuclear medicine practitioners together to discuss the advances in four selected areas of imaging: Biochemical Parameters using Small Animal Imaging, Developments in Small Animal PET Imaging, Cell Labeling, and Imaging Angiogenesis Using Multiple Modality. The presentations will be on molecular imaging applications at the forefront of research, up to date on the status of molecular imaging in nuclear medicine as well as in related imaging areas. Experts will discuss the basic science of imaging techniques, and scheduled participants will engage in an exciting program that emphasizes the current status of molecular imaging as well as the role of DOE funded research in this area
Recommended from our members
Translational Applications of Molecular Imaging and Radionuclide Therapy
Molecular imaging is becoming a larger part of imaging research and practice. The Office of Biological and Environmental Research of the Department of Energy funds a significant number of researchers in this area. The proposal is to partially fund a workshop to inform scientists working in nuclear medicine and nuclear medicine practitioners of the recent advances of molecular imaging in nuclear medicine as well as other imaging modalities. A limited number of topics related to radionuclide therapy will also be discussed. The proposal is to request partial funds for the workshop entitled âTranslational Applications of Molecular Imaging and Radionuclide Therapyâ to be held prior to the Society of Nuclear Medicine Annual Meeting in Toronto, Canada in June 2005. The meeting will be held on June 17-18. This will allow scientists interested in all aspects of nuclear medicine imaging to attend. The chair of the organizing group is Dr. Michael J. Welch. The organizing committee consists of Dr. Welch, Dr. William C. Eckelman and Dr. David Vera. The goal is to invite speakers to discuss the most recent advances of modern molecular imaging and therapy. Speakers will present advances made in in vivo tagging imaging assays, technical aspects of small animal imaging, in vivo imaging and bench to bedside translational study â the role of a diagnostic scan on therapy selection. This latter topic will include discussions on α therapy and new approaches to dosimetry. Several of these topics are those funded by the Department of Energy Office of Biological and Environmental Research
Experiment assessment of mass effects in the rat_ implications for small animal PET imaging
In vivo imaging using positron emission tomography (PET) is important in the development of new radiopharmaceuticals in rodent
animal models for use as biochemical probes, diagnostic agents, or in drug development. We have shown mathematically that, if small
animal imaging studies in rodents are to have the same âqualityâ as human PET studies, the same number of coincidence events must be
detected from a typical rodent imaging âvoxelâ as from the human imaging voxel. To achieve this using the same specifi activity
preparation, we show that roughly the same total amount of radiopharmaceutical must be given to a rodent as to a human subject. At high
specifi activities, the mass associated with human doses, when administered to a rodent, may not decrease the uptake of radioactivity at
non saturable sites or sites where an enzyme has a high capacity for a substrate. However, in the case of binding sites of low density such
as receptors, the increased mass injected could saturate the receptor and lead to physiologic effects and non-linear kinetics. Because of the
importance of the mass injected for small animal PET imaging, we experimentally compared high and low mass preparations using ex vivo
biodistribution and phosphorimaging of three compounds: 2-fluoro-2-deoxyglucos (FDG), 6-fluoro-L-metatyrosin (FMT) and one
receptor-directed compound, the serotonin 5HT1A receptor ligand, trans-4-fluoro-N-{2-[4-(2-methoxylphenyl piperazino]ethyl}-N-(2-
pyridyl) cyclohexane- carboxamide (FCWAY). Changes in the mass injected per rat did not affect the distribution of FDG, FMT, and
FCWAY in the range of 0.6 â1.9 nmol per rat. Changes in the target to nontarget ratio were observed for injected masses of FCWAY in
the range of 5â50 nmol per rat. If the specifi activity of such compounds and/or the sensitivity of small animal scanners are not increased
relative to human studies, small animal PET imaging will not correctly portray the âtrueâ tracer distribution. These difficultie will only be
exacerbated in animals smaller than the rat, e.g., mice.Publicad
Initial results from a PET/planar small animal imaging system
A pair of stationary, opposed scintillation detectors in time
coincidence is being used to create planar projection or
tomographic images of small animals injected with positronemitting
radiotracers. The detectors are comprised of arrays
of individual crystals of bismuth germanate coupled to
position-sensitive photomultiplier tubes. The system uses
FERA (LeCroy Research Systems) charge-sensitive ADCs
and a low cost digital YO board as a E R A bus-to-host bridge.
In projection mode, the animal is placed within the 55 mm x
45 mm useful field-of-view of the detectors and images are
formed from coincidence lines that fall close to the normals of
both detectors. In tomographic mode, the animal is placed on
a rotation stage between the detectors and rotated around a
vertical axis to acquire all possible lines-of-response.
Tomographic images are then reconstructed from those lines
falling within a user-specified angle of each detector normal.
In mice, the system is capable of high-speed, whole-body
dynamic projection imaging, and whole body tomographic
imaging of slowly varying tracer distributions. An ECG gating capability is also available for evaluating cardiac
function. This system is currently being used to study tracer
transport in normal and genetically engineered mice.Publicad
High resolution PET, SPECT and projection imaging in small animals
Positron emission tomography, single photon emission computed tomography and planar projection imaging of radioactive tracers have long been in use for detecting and diagnosing disease in human subjects. More recently, advanced versions of these same technologies have begun to be used across the breadth of modern biomedical research to study non-invasively small laboratory animals in a myriad of experimental settings. In this report, we describe some of the new instruments and techniques that make these measurements possible and illustrate, with a few examples, the potential power of these methods in modern biomedical researchPublicad
Fast 18F Labeling of a Near-Infrared Fluorophore Enables Positron Emission Tomography and Optical Imaging of Sentinel Lymph Nodes
We combine a novel boronate trap for Fâ with a near-infrared fluorophore into a single molecule. Attachment to targeting ligands enables localization by positron emission tomography (PET) and near-infrared fluorescence (NIRF). Our first application of this generic tag is to label Lymphoseek (tilmanocept), an agent designed for receptor-specific sentinel lymph node (SLN) mapping. The new conjugate incorporates 18Fâ in a single, aqueous step, targets mouse SLN rapidly (1 h) with reduced distal lymph node accumulation, permits PET or scintigraphic imaging of SLN, and enables NIRF-guided excision and histological verification even after 18F decay. This embodiment is superior to current SLN mapping agents such as nontargeted [99mTc]sulfur colloids and Isosulfan Blue, as well as the phase III targeted ligand [99mTc]SPECT Lymphoseek counterpart, species that are visible by SPECT or visible absorbance separately. Facile incorporation of 18F into a NIRF probe should promote many synergistic PET and NIRF combinations
Monitoring the correction of glycogen storage disease type 1a in a mouse model using [18F]FDG and a dedicated animal scanner
Monitoring gene therapy of glycogen storage disease type 1a in a mouse model was achieved using [18F]FDG and a dedicated animal scanner. The G6Pase knockout (KO) mice were compared to the same mice after infusion with a recombinant adenovirus containing the murine G6Pase gene (Ad-mG6Pase). Serial images of the same mouse before and after therapy were obtained and compared with wild-type (WT) mice of the same strain to determine the uptake and retention of [18F]FDG in the liver. Image data were acquired from heart, blood pool and liver for twenty minutes after injection of [18F]FDG. The retention of [18F]FDG was lower for the WT mice compared to the KO mice. The mice treated with adenovirus-mediated gene therapy had retention similar to that found in age-matched WT mice. These studies show that FDG can be used to monitor the G6Pase concentration in liver of WT mice as compared to G6Pase KO mice. In these mice, gene therapy returned the liver function to that found in age matched WT controls as measured by the FDG kinetics in the liver compared to that found in age matched wild type controlsPublicad
Biomedical imaging research opportunities workshop IV: A white paper
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/134967/1/mp5838.pd
[68Ga]Ga-P16-093 as a PSMA-Targeted PET Radiopharmaceutical for Detection of Cancer: Initial Evaluation and Comparison with [68Ga]Ga-PSMA-11 in Prostate Cancer Patients Presenting with Biochemical Recurrence
Purpose: This study was undertaken to evaluate radiation dosimetry for the prostate-specific membrane antigen targeted [68Ga]Ga-P16-093 radiopharmaceutical, and to initially assess agent performance in positron emission tomography (PET) detection of the site of disease in prostate cancer patients presenting with biochemical recurrence.
Procedures: Under IND 133,222 and an IRB-approved research protocol, we evaluated the biodistribution and pharmacokinetics of [68Ga]Ga-P16-093 with serial PET imaging following intravenous administration to ten prostate cancer patients with biochemical recurrence. The recruited subjects were all patients in whom a recent [68Ga]Ga-PSMA-11 PET/X-ray computed tomography (CT) exam had been independently performed under IND 131,806 to assist in decision-making with regard to their clinical care. Voided urine was collected from each subject at ~ 60 min and ~ 140 min post-[68Ga]Ga-P16-093 injection and assayed for Ga-68 content. Following image segmentation to extract tissue time-activity curves and corresponding cumulated activity values, radiation dosimetry estimates were calculated using IDAC Dose 2.1. The prior [68Ga]Ga-PSMA-11 PET/CT exam (whole-body PET imaging at 60 min post-injection, performed with contrast-enhanced diagnostic CT) served as a reference scan for comparison to the [68Ga]Ga-P16-093 findings.
Results: [68Ga]Ga-P16-093 PET images at 60 min post-injection provided diagnostic information that appeared equivalent to the subject's prior [68Ga]Ga-PSMA-11 scan. With both radiopharmaceuticals, sites of tumor recurrence were found in eight of the ten patients, identifying 16 lesions. The site of recurrence was not detected with either agent for the other two subjects. Bladder activity was consistently lower with [68Ga]Ga-P16-093 than [68Ga]Ga-PSMA-11. The kidneys, spleen, salivary glands, and liver receive the highest radiation exposure from [68Ga]Ga-P16-093, with estimated doses of 1.7 Ă 10-1, 6.7 Ă 10-2, 6.5 Ă 10-2, and 5.6 Ă 10-2 mGy/MBq, respectively. The corresponding effective dose from [68Ga]Ga-P16-093 is 2.3 Ă 10-2 mSv/MBq.
Conclusions: [68Ga]Ga-P16-093 provided diagnostic information that appeared equivalent to [68Ga]Ga-PSMA-11 in this limited series of ten prostate cancer patients presenting with biochemical recurrence, with the kidneys found to be the critical organ. Diminished tracer appearance in the urine represents a potential advantage of [68Ga]Ga-P16-093 over [68Ga]Ga-PSMA-11 for detection of lesions in the pelvis
Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018.
Over the past decade, the Nomenclature Committee on Cell Death (NCCD) has formulated guidelines for the definition and interpretation of cell death from morphological, biochemical, and functional perspectives. Since the field continues to expand and novel mechanisms that orchestrate multiple cell death pathways are unveiled, we propose an updated classification of cell death subroutines focusing on mechanistic and essential (as opposed to correlative and dispensable) aspects of the process. As we provide molecularly oriented definitions of terms including intrinsic apoptosis, extrinsic apoptosis, mitochondrial permeability transition (MPT)-driven necrosis, necroptosis, ferroptosis, pyroptosis, parthanatos, entotic cell death, NETotic cell death, lysosome-dependent cell death, autophagy-dependent cell death, immunogenic cell death, cellular senescence, and mitotic catastrophe, we discuss the utility of neologisms that refer to highly specialized instances of these processes. The mission of the NCCD is to provide a widely accepted nomenclature on cell death in support of the continued development of the field
- âŠ